

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

---

**UNAUDITED**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**CONTENTS**

---

	Page
<b>Reference and administrative details of the Company, its Trustees and advisers</b>	1
<b>Trustees' report</b>	2 - 8
<b>Independent examiner's report</b>	9 - 10
<b>Statement of financial activities</b>	11
<b>Balance sheet</b>	12 - 13
<b>Notes to the financial statements</b>	14 - 30

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**Trustees**

Professor Andrew Shennan OBE, Chairman  
Professor Jenny Myers, Trustee  
Dr Kim Turner, Chairman  
Dr Lucy MacKillop, Trustee  
Dr Carol Cooper, Trustee  
Dr Carol Lole-Harris, Trustee  
Dr Sarah Winfield, Trustee  
Dr Anita Banerjee, Trustee  
Dr Kate Harding, Trustee  
Dr Louise Webster, Trustee  
Dianne Garland, Trustee  
Vijya Varshani, Trustee  
Darren Reece, Trustee  
Rob Crussell, Trustee

**Honorary Medical Director:** Professor Emeritus James Walker; MD FRCP FRCPS MBChB FRCOG

**Chief Executive:** Marcus Green BA Hons, FRSA, FRSPH

**Company registered number** 02736320

**Charity registered number** 1013557

**Registered office** The Stables  
80B High Street  
Evesham  
Worcestershire  
WR11 4EU

**Telephone** 01386 761848  
**Email** [info@apec.org.uk](mailto:info@apec.org.uk)  
**Website** [www.apec.org.uk](http://www.apec.org.uk)  
**Social media** links [https://linktr.ee/apec\\_uk](https://linktr.ee/apec_uk)

**Accountants** Donald Reid Limited  
Chartered Accountants  
Prince Albert House  
20 King Street  
Maidenhead  
Berkshire  
SL6 1DT

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**TRUSTEES' REPORT**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

The Trustees present their annual report together with the financial statements of the Action on Pre-Eclampsia Limited for the year 1 January 2023 to 31 December 2023. The Annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the Annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the Company qualifies as small under section 382 of the Companies Act 2006, the Strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

**Objectives and activities**

**a. Policies and objectives**

The purposes of the charity are as set out in its governing document:

- To educate, inform and advise the public and health professionals about the prevalence, nature and risks of pre-eclampsia and eclampsia;
- To campaign for greater public awareness of the disease and for action to improve methods of detection and treatment; and
- To promote the relief of persons who suffer preeclampsia and to relieve the stress of families of such persons

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

**b. Strategies for achieving objectives**

The charity is governed by a Board of Trustees who meet on a regular basis both virtually and face to face. On a day to basis decision making is delegated to the Chief Executive and the small staff based in the Evesham office.

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

---

**TRUSTEES' REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**Objectives and activities (continued)**

**c. Activities undertaken to achieve objectives**

- During the year we undertook study days for midwives and student midwives. We provided a free elearning package to increase the number of people reached and raised awareness through our social media channels. We are enormously grateful to the institutions, midwifery societies and hospitals who hosted us as well as the very many speakers who volunteered their time.

- We ran a highly successful online Experts Day online to share knowledge and experience. This was attended by a record number of senior clinicians. This was an opportunity for many of the leading thinkers in the field to come together and discuss progress on research in preeclampsia. We are very grateful for the number of speakers who freely gave their time to this important event which continues to grow in scale and significance year on year. Running the Expert's Day online has proven to be a successful formula and we anticipate growing and developing this as it is both cost and time effective.

- We offered, and continue to offer, support to families affected by preeclampsia through our helpline, email and social media presence. We offer verbal support, a listening ear, contact with others who have been through similar experiences and immediate referral to experts where needed. This has been especially important when mothers to be have been concerned about symptoms they may be getting. On a number of occasions women have telephoned and afterwards have felt empowered to move forward with their treatment. There have been repeated examples throughout the year when we have been able to refer women who have had problems in the past to experts in the field who have been able to advise them. We remain truly grateful to the world leading experts throughout the UK who have continued to support the helpline activities and been able to advise accordingly.

- We continue to offer support to researchers and trials ensuring that the views of women and families are heard at every level. This year has seen an escalation in the number of trials that we are supporting. In the United Kingdom it is often the case that if you wish to apply for research funding, the voice of the patient has to be heard and we have collaborated as co-investigator on a number of trials as well as providing informal and formal advice to others. During the year we undertook a number of study days for midwives and student midwives. We provided a free elearning package to increase the number of people reached and raised awareness through our social media channels.

**d. Main activities undertaken to further the Company's purposes for the public benefit**

The main activities of the charity have been to:

- Run a helpline for concerned sufferers, their families, and professionals
- Provide training for health professionals via Study Days and online training
- Support world class research
- Raise awareness of pre-eclampsia amongst interested parties
- Campaign for better care and treatment for sufferers especially including Placental Growth Factor Testing
- Influence the wider debate on healthcare for expectant families

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

---

**TRUSTEES' REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**Achievements and performance**

**a. Main achievements of the Company**

**Training for Midwives**

During the year we held a number of Study Days:

Poole 18/01/23  
London Online 20/03/23  
Milton Keynes 20/03/23  
Milton Keynes 11/05/23  
Manchester 15/06/23  
Birmingham 23/06/23  
Wakefield 18/10/23  
East Kent 19/10/23  
Hastings 01/12/23

**Online Training**

After a radical overhaul of the training in 2018 to our training programme, online training has bedded in well. The course was written by experts led by trustee Prof Kim Turner and a team who contributed from throughout the world. The course is aimed at midwives, though GP's and AHP's have also participated.

This has supported our belief that pre-eclampsia is a global issue and our resources need to be made available freely where they are most needed.

**Helpline**

Our helpline has continued to offer support primarily to parents; we have seen a considerable rise in contacts over the year. We have attributed this to concern over covid. We have especially seen a growth in calls from fathers to be. Where appropriate calls have been passed to our experts and we thank the very many clinical leaders who have taken cases on our behalf, often at a point of crisis and out of hours.

We have been called in to help on significantly complex problems where parents need support to get reports out of the NHS, especially where a baby has died. These cases require patience and diligence and can take many months of work and support.

We continue to recognize the need for holistic care that includes the whole family and we work to support partners as well as sufferers.

**Research**

APEC is involved in research into the causes, treatments and development of knowledge about pre-eclampsia. We firmly believe that the patient voice has to be at the heart of research and without it, research is much harder.

We are involved at every stage from study design through to publication and post publication dissemination to a wider audience.

This was a year with many new papers and we were proud to collaborate on the following research outputs

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

---

**TRUSTEES' REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**Achievements and performance (continued)**

**Using self-monitoring to detect and manage raised blood pressure and pre-eclampsia during pregnancy: the BUMP research programme and its impact**

Published in Hypertension Research, December 7th 2023

Katherine L. Tucker, Lisa Hinton, Marcus Green, Lucy C. Chappell & Richard J. McManus

**A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA)**

Published in September 2023

Danielle Ashworth, Cheryl Battersby, Debra Bick, Marcus Green, Pollyanna Hardy, Lisa Leighton, Laura A. Magee, Alisha Maher, Richard J. McManus, Catherine Moakes, R. Katie Morris, Catherine Nelson-Piercy, Jenie Sparkes, Oliver Rivero-Arias, Andrew Webb, Hannah Wilson, Jenny Myers, Lucy C. Chappell

**Hypertensive disorders of pregnancy**

Published in BMJ, June 2023

Pensée Wu, Marcus Green, Jenny E Myers

**'Nesting networks': Women's experiences of social network support in high-risk pregnancy care through the lens of candidacy**

Published in Midwifery, May 2023

L. Hinton, C. Dumelow, J. Hodgkinson, C. Montgomery, A. Martin, C. Allen, K Tucker, M.E. Green, H. Wilson, R.J. McManus, L.C. Chappell, R. Band

**A qualitative study of the dynamics of access to remote antenatal care through the lens of candidacy**  
**Published in Journal of Health Services Research & Policy, 21 April 2023**

Lisa Hinton, Karolina Kuberska, Francesca Dakin, Nicola Boydell, Graham Martin, Tim Draycott, Cathy Winter, Richard J McManus, Lucy Chappell, Sanhita Chakrabarti, Elizabeth Howland, Janet Willars, Mary Dixon-Woods

**Supporting Research into pre-eclampsia – charity spotlight**

Published in BMJ Vol 31 p212, April 2023

Andrew H Shennan, Dianne Garland, Marcus Green

**Experts Day**

Our Experts Day saw a significant attendance and including presentations from

Prof Lucy Chappell, Dr Alex Ridout, Dr Veronica Giorgione, Dr Alice Beardmore-Gray, Dr Laura Ormesher, Milly Wilson, Dr Katy Kuhrt, Dr Anna Davies, Raya Vinogradov, Layla Lavalley, Dr Olivia Moran, Dr Natalie Dennehy, Lucy Goddard, Dr Laura van der Krogt, Dr Kylie Belchamber, Prof Marian Knight, Dr Bernadette Jenner, Dr Katherine Tucker, Dr Jamie Kitt, Dr Kaspar Phil, Dr Lisa Hinton, Dr Catherine Aitken, Prof Stefan Verlohren, Prof Asma Khalil, Prof Jenny Myers, Prof Basky Thilaganathan, Nigel Clarke & Thomas Partington, Prof Andrew Shennan, Dr Komommo Irwara, Prof Sue Steen, Koiwah Koi-Larbi, Dr Alice Hurrell, Dr Kate Duhig, Bea Cadwallader, Dr Federica Piani and many others

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**TRUSTEES' REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**Financial review**

**a. Going concern**

After making appropriate enquiries, the Trustees have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

**b. Reserves policy**

In the trustees' view, the reserves should provide the charity with adequate financial stability and the means for it to meet its charitable objectives for the foreseeable future.

The trustees propose to maintain the charity's reserves at a level which is at least equivalent to six months' operational expenditure and have done so having regards to its manner of operation of likely funding streams.

The trustees review the amount of reserves that are required to ensure that they are adequate to fulfil the charity's continuing obligations on a quarterly basis at their trustee meeting.

Trustees are content that reserves are at a satisfactory level given the size, scope and risks to the charity at the current time. The trustees plan that the charity is a going concern and have no uncertainties other than managed risks about this.

**Structure, governance and management**

**a. Constitution**

Action on Pre-Eclampsia Limited is registered as a charitable company limited by guarantee and was set up by a Trust deed.



---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**TRUSTEES' REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**Structure, governance and management (continued)**

**b. Methods of appointment or election of Trustees**

The charity is a company and charity and follows the legislation pertaining to both. The charity is governed by its Articles and Memorandum in a trust document from 1992. Trustees are satisfied that these documents meet the needs of the charity, now and into the future.

Trustees are appointed from within the membership. The governing document allows for between 5 and 13 trustees and there are currently 15. A vote at the AGM in 2020 allowed for a wider trustee board during the pandemic and in the aftermath.

To appoint trustees, APEC follow the Charity Commission guidelines. Specifically, we:

- Identify the need
- Agree the skills and experiences we require and create a person and role specification
- Agree an open process of recruitment
- Ensure that we are opening the opportunity to a diverse range of candidates
- Interview against the criteria we have identified, in a fair and objective manner
- Invite preferred candidates to join subject to reference
- Get written confirmation that candidates are eligible in law to be trustees
- Ask candidates to declare conflicts of interest
- Formalise the appointment in line with our governing document
- The chair writes to candidates setting out their duties and responsibilities as trustees and directors
- A formal induction process is undertaken
- Trustees are formally welcomed to the board
- The decision is ratified at the next AGM

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

---

**TRUSTEES' REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**Statement of Trustees' responsibilities**


The Trustees (who are also the directors of the Company for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 18 September 2024 and signed on their behalf by:



|

**Professor Andrew Shennan OBE**  
(Chair of Trustees)

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**Independent Examiner's Report to the Trustees of Action on Pre-Eclampsia Limited ('the Company')**

I report to the charity Trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

**Responsibilities and Basis of Report**

As the Trustees of the Company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Company's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent Examiner's Statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

This report is made solely to the Company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Company's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Company and the Company's Trustees as a body, for my work or for this report.



Signed:

Dated: 25 September 2024

Daniel Reid FCA

Donald Reid Limited  
Chartered Accountants  
Prince Albert House  
20 King Street  
Maidenhead  
SL6 1DT

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Note	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
<b>Income from:</b>				
Donations and legacies	3	72,074	72,074	71,287
Other trading activities	4	172,050	172,050	127,955
Investments	5	3,040	3,040	317
<b>Total income</b>		<b>247,164</b>	<b>247,164</b>	<b>199,559</b>
<b>Expenditure on:</b>				
Raising funds	6	23,083	23,083	27,609
Charitable activities	7	145,783	145,783	127,123
<b>Total expenditure</b>		<b>168,866</b>	<b>168,866</b>	<b>154,732</b>
<b>Net movement in funds</b>		<b>78,298</b>	<b>78,298</b>	<b>44,827</b>
<b>Reconciliation of funds:</b>				
Total funds brought forward		223,161	223,161	178,334
Net movement in funds		78,298	78,298	44,827
<b>Total funds carried forward</b>		<b>301,459</b>	<b>301,459</b>	<b>223,161</b>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 14 to 30 form part of these financial statements.

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**  
**REGISTERED NUMBER: 02736320**

**BALANCE SHEET**  
**AS AT 31 DECEMBER 2023**

	Note	2023 £	2022 £
<b>Fixed assets</b>			
Tangible assets	12	938	561
		<u>938</u>	<u>561</u>
<b>Current assets</b>			
Stocks	13	1,314	1,875
Debtors	14	25,228	14,828
Cash at bank and in hand		275,488	207,456
		<u>302,030</u>	<u>224,159</u>
Creditors: amounts falling due within one year	15	(1,509)	(1,559)
<b>Net current assets</b>		<u>300,521</u>	<u>222,600</u>
<b>Total assets less current liabilities</b>		<u>301,459</u>	<u>223,161</u>
<b>Net assets excluding pension asset</b>		<u>301,459</u>	<u>223,161</u>
<b>Total net assets</b>		<u><u>301,459</u></u>	<u><u>223,161</u></u>
<b>Charity funds</b>			
Restricted funds	17	-	-
Unrestricted funds	17	301,459	223,161
<b>Total funds</b>		<u><u>301,459</u></u>	<u><u>223,161</u></u>

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**  
**REGISTERED NUMBER: 02736320**

---

**BALANCE SHEET (CONTINUED)**  
**AS AT 31 DECEMBER 2023**

---

The Company was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees on 18 September 2024 and signed on their behalf by:



|

**Professor Andrew Shennan OBE**  
(Chair of Trustees)

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**1. General information**

The charity is a company limited by guarantee and is incorporated in England and Wales with the company registration number 02736320 and the registered charity number 1013557.

**2. Accounting policies**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Action on Pre-Eclampsia Limited meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

**2.2 Income**

All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of financial activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Gifts in kind donated for distribution are included at valuation and recognised as income when they are distributed to the projects. Gifts donated for resale are included as income when they are sold.

Where the donated good is a fixed asset, it is measured at fair value, unless it is impractical to measure this reliably, in which case the cost of the item to the donor should be used. The gain is recognised as income from donations and a corresponding amount is included in the appropriate fixed asset class and depreciated over the useful economic life in accordance with the Company's accounting policies.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the Company which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.



---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**2. Accounting policies (continued)**

**2.3 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Company to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Company's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

**2.4 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Company; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

**2.5 Tangible fixed assets and depreciation**

Tangible fixed assets costing £NIL or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, .

Depreciation is provided on the following basis:

Plant and machinery	- 30% reducing balance
---------------------	------------------------

**2.6 Stocks**

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**2. Accounting policies (continued)**

**2.7 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2.8 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**2.9 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

**2.10 Financial instruments**

The Company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**2.11 Pensions**

The Company operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Company to the fund in respect of the year.

**2.12 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Company and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**3. Income from donations and legacies**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Donations	58,074	<b>58,074</b>
Grants	14,000	<b>14,000</b>
	<u>72,074</u>	<u><b>72,074</b></u>

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Donations	57,787	57,787
Grants	9,500	9,500
Sponsorship	4,000	4,000
	<u>71,287</u>	<u>71,287</u>

**4. Income from other trading activities**

**Income from fundraising events**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Marathon income and other fundraising events	124,090	<b>124,090</b>

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Marathon income and other fundraising events	94,438	94,438

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**4. Income from other trading activities (continued)**

**Income from non charitable trading activities**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Charity trading income - blood pressure monitors and books	47,960	<b>47,960</b>

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Charity trading income - blood pressure monitors and books	33,517	33,517

**5. Investment income**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Investment income - bank interest receivable	3,040	<b>3,040</b>

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Investment income - bank interest receivable	317	317

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**6. Expenditure on raising funds**

**Costs of raising voluntary income**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Marathon costs	6,945	<b>6,945</b>
Study day event costs	370	<b>370</b>
Publicity, brochures and material	1,032	<b>1,032</b>
	<u>8,347</u>	<u><b>8,347</b></u>

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Marathon costs	14,797	14,797
Publicity, brochures and material	582	582
	<u>15,379</u>	<u>15,379</u>

**Fundraising trading expenses**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Miscellaneous fundraising costs	2,420	<b>2,420</b>

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Miscellaneous fundraising costs	931	931

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**6. Expenditure on raising funds (continued)**

**Other trading expenses**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Purchases	12,316	<b>12,316</b>

**Other trading expenses (continued)**

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Purchases	11,299	11,299

**7. Analysis of expenditure on charitable activities**

**Summary by fund type**

	<b>Unrestricted funds 2023 £</b>	<b>Total 2023 £</b>
Direct costs	145,783	<b>145,783</b>

	<i>Unrestricted funds 2022 £</i>	<i>Total 2022 £</i>
Direct costs	127,123	127,123

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**7. Analysis of expenditure on charitable activities (continued)**

**Summary by expenditure type**

	<b>Staff costs 2023 £</b>	<b>Depreciation 2023 £</b>	<b>Other costs 2023 £</b>	<b>Total 2023 £</b>
Expenditure on charitable activities	66,536	327	78,920	<b>145,783</b>

	<i>Staff costs 2022 £</i>	<i>Depreciation 2022 £</i>	<i>Other costs 2022 £</i>	<i>Total 2022 £</i>
Expenditure on charitable activities	34,701	149	92,273	127,123

**8. Analysis of expenditure by activities**

	<b>Activities undertaken directly 2023 £</b>	<b>Support costs 2023 £</b>	<b>Total funds 2023 £</b>
Charitable activities	61,142	84,641	<b>145,783</b>

	<i>Activities undertaken directly 2022 £</i>	<i>Support costs 2022 £</i>	<i>Total funds 2022 £</i>
Charitable activities	37,784	89,339	127,123

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**8. Analysis of expenditure by activities (continued)**

**Analysis of direct costs**

	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Staff costs	<b>49,916</b>	26,041
International development	<b>4,410</b>	3,510
Travel and subsistence	<b>2,329</b>	1,839
Marketing and advertising of charitable services	<b>1,617</b>	1,260
Expert meetings and study day costs	<b>150</b>	410
Website	<b>2,180</b>	4,624
Leaflet costs	<b>540</b>	100
	<hr/> <b>61,142</b> <hr/>	<hr/> 37,784 <hr/>



**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**8. Analysis of expenditure by activities (continued)**

**Analysis of support costs**

	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Staff costs	<b>16,620</b>	8,660
Depreciation	<b>327</b>	149
Staff training	<b>22</b>	280
Management consultancy	<b>46,901</b>	60,462
Governance - accountancy and independent examination	<b>1,087</b>	4,187
Legal and professional fees	<b>35</b>	35
Bank charges	<b>60</b>	73
IT support	<b>5,071</b>	2,720
Rent	<b>6,320</b>	6,000
Light, heat and power	<b>1,678</b>	2,427
Telephone, fax and internet	<b>738</b>	847
Stationery and printing	<b>1,247</b>	1,061
Liability and contents insurance	<b>465</b>	519
Resource costs	<b>3,775</b>	1,818
Governance costs - Trustees' expenses reimbursed	<b>295</b>	101
	<b>84,641</b>	89,339

**9. Independent examiner's remuneration**

	<b>2023 £</b>	<i>2022 £</i>
Fees payable to the Company's independent examiner for the independent examination of the Company's annual accounts	<b>1,080</b>	1,080
Fees payable to the Company's independent examiner in respect of:		
All other services not included above	<b>-</b>	2,400

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**10. Staff costs**

	<b>2023</b> £	<i>2022</i> £
Wages and salaries	<b>64,757</b>	33,724
Contribution to defined contribution pension schemes	<b>1,779</b>	977
	<u><b>66,536</b></u>	<u>34,701</u>

The average number of persons employed by the Company during the year was as follows:

	<b>2023</b> No.	<i>2022</i> No.
Engaged on fundraising activities	<b>2</b>	1
Engaged on management and administration	<b>1</b>	1
	<u><b>3</b></u>	<u>2</u>

No employee received remuneration amounting to more than £60,000 in either year.

During the period key management personnel received salary of £19,175 (*2022: £nil*) and pension contributions of £574 (*2022: £nil*).

**11. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (*2022 - £NIL*).

During the year ended 31 December 2023, expenses totalling £295 were reimbursed or paid directly to 3 Trustees (*2022 - £101 to 1 Trustee*). The expenses reimbursed related to travel in each period.

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**12. Tangible fixed assets**

	Plant and machinery £
<b>Cost or valuation</b>	
At 1 January 2023	961
Additions	704
At 31 December 2023	<u>1,665</u>
<b>Depreciation</b>	
At 1 January 2023	400
Charge for the year	327
At 31 December 2023	<u>727</u>
<b>Net book value</b>	
At 31 December 2023	<u>938</u>
<i>At 31 December 2022</i>	<u>561</u>

**13. Stocks**

	2023 £	2022 £
Finished goods and goods for resale	<u>1,314</u>	<u>1,875</u>

**14. Debtors**

	2023 £	2022 £
<b>Due within one year</b>		
Other debtors	9,510	4,693
Prepayments and accrued income	15,718	10,135
	<u>25,228</u>	<u>14,828</u>

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**15. Creditors: Amounts falling due within one year**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Accruals and deferred income	<b>1,509</b>	<b>1,559</b>

**16. Financial instruments**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
<b>Financial assets</b>		
Financial assets measured at amortised costs through income and expenditure	<b>284,998</b>	<b>212,149</b>
	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
<b>Financial liabilities</b>		
Other financial liabilities measured at amortised cost through income and expenditure	<b>1,509</b>	<b>1,559</b>

Financial assets measured at amortised cost through income and expenditure comprise bank and other debtors.

Other financial liabilities measured at amortised cost through income and expenditure comprise accruals.

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**17. Statement of funds**

**Statement of funds - current year**

	Balance at 1 January 2023 £	Income £	Expenditure £	Balance at 31 December 2023 £
<b>Unrestricted funds</b>				
<b>Designated funds</b>				
Redman Walker Award Fund	19,500	-	-	19,500
 <b>General funds</b>				
General Funds - all funds	203,661	247,164	(168,866)	281,959
 <b>Total Unrestricted funds</b>	<b>223,161</b>	<b>247,164</b>	<b>(168,866)</b>	<b>301,459</b>

The Charity set up the Redman Walker Award in 2017. The trustees have created a designated fund in order to finance the Redman Walker Award, which has been designed to recognise the efforts of young researchers. The award will work on an annual cycle with up to two awards of £500 a year.

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**17. Statement of funds (continued)**

**Statement of funds - prior year**

	<i>Balance at 1 January 2022 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Balance at 31 December 2022 £</i>
<b>Unrestricted funds</b>				
<b>Designated funds</b>				
Redman Walker Award Fund	19,500	-	-	19,500
<b>General funds</b>				
General Funds - all funds	158,834	199,559	(154,732)	203,661
<b>Total Unrestricted funds</b>	<u>178,334</u>	<u>199,559</u>	<u>(154,732)</u>	<u>223,161</u>

**18. Summary of funds**

**Summary of funds - current year**

	<b>Balance at 1 January 2023 £</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>Balance at 31 December 2023 £</b>
Designated funds	19,500	-	-	19,500
General funds	203,661	247,164	(168,866)	281,959
	<u>223,161</u>	<u>247,164</u>	<u>(168,866)</u>	<u>301,459</u>

**ACTION ON PRE-ECLAMPSIA LIMITED**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**18. Summary of funds (continued)**

**Summary of funds - prior year**

	<i>Balance at 1 January 2022 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Balance at 31 December 2022 £</i>
Designated funds	19,500	-	-	19,500
General funds	158,834	199,559	(154,732)	203,661
	<u>178,334</u>	<u>199,559</u>	<u>(154,732)</u>	<u>223,161</u>

**19. Analysis of net assets between funds**

**Analysis of net assets between funds - current year**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Tangible fixed assets	938	<b>938</b>
Current assets	302,030	<b>302,030</b>
Creditors due within one year	(1,509)	<b>(1,509)</b>
<b>Total</b>	<u>301,459</u>	<u><b>301,459</b></u>

**Analysis of net assets between funds - prior year**

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Tangible fixed assets	561	561
Current assets	224,159	224,159
Creditors due within one year	(1,559)	(1,559)
<b>Total</b>	<u>223,161</u>	<u>223,161</u>

---

**ACTION ON PRE-ECLAMPSIA LIMITED**  
**(A company limited by guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

---

**20. Pension commitments**

The Charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Charity in an independently administered fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £1,779 (2022 - £977) No sums were outstanding within liabilities at either the current or prior period end date.